Biotech · Private company
Ambrx, Inc.
Track this companyFree. Adds Ambrx, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ARX788Phase 2 · HER2 Mutation-Related TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ARX788Phase 2 · HER2 Positive Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ARX788Phase 1 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerPHASE2 · RECRUITING · started Jun 5, 2026ClinicalTrials.gov NCT06224673 · fetched Nov 12, 2026
- ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)PHASE2 · WITHDRAWN · started Nov 5, 2021ClinicalTrials.gov NCT05041972 · fetched Nov 12, 2026
- ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 26, 2021ClinicalTrials.gov NCT04829604 · fetched Nov 12, 2026
- A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)PHASE1 · COMPLETED · started Mar 20, 2018ClinicalTrials.gov NCT03255070 · fetched Nov 12, 2026